f The Rise of FLiRT Variants in the COVID-19 Pandemic: What we Know so Far

References

1. DonnellyS.C. FLiRT a dominant COVID variant responsible for a summer surge in COVID infections.QJM202411748310.1093/qjmed/hcae127
   [Google Scholar]
2. AdenD. ZaheerS. Investigating the FLiRT variants of COVID-19: Is it an emerging concern?Pathol. Res. Pract.202426215554210.1016/j.prp.2024.155542 39178510
   [Google Scholar]
3. KumarP. JayanJ. SharmaR.K. GaidhaneA.M. ZahiruddinQ.S. RustagiS. The emerging challenge of FLiRT variants: KP.1.1 and KP.2 in the global pandemic landscape.QJM2024117485487
   [Google Scholar]
4. YangW.T. HuangW.H. LiaoT.L. HsiaoT.H. ChuangH.N. LiuP.Y. SARS-CoV-2 E484K mutation narrative review: Epidemiology, immune escape, clinical implications, and future considerations.Infect. Drug Resist.20221537338510.2147/IDR.S344099 35140483
   [Google Scholar]
5. ZamudioM. TanC. DorpL. BallouxF. Early evolution of the BA. 2.86 variant sheds light on the origins of highly divergent SARS-CoV-2 lineages.bioRxiv20240718604213202410.1101/2024.07.18.604213
   [Google Scholar]
6. LiP. FaraoneJ.N. HsuC.C. Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion.bioRxiv20240520595020202410.1101/2024.05.20.595020
   [Google Scholar]
7. PondéR.A.A. Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern.Virology2022572445410.1016/j.virol.2022.05.003 35580380
   [Google Scholar]
8. CarabelliA.M. PeacockT.P. ThorneL.G. SARS-CoV-2 variant biology: Immune escape, transmission and fitness.Nat. Rev. Microbiol.202321316217710.1038/s41579‑022‑00841‑7 36653446
   [Google Scholar]
9. MaqboolM. HussainM.S. ShaikhN.K. SultanaA. BishtA.S. AgrawalM. Noncoding RNAs in the COVID-19 Saga: An untold story.Viral Immunol.202437626928610.1089/vim.2024.0026 38968365
   [Google Scholar]
10. AdzragoD. SulleyS. OrmistonC.K. WilliamsF. Socioeconomic and clinical risk factors associated with moderate intensity physical activity before and during the COVID-19 pandemic.Prev. Med. Rep.20243710255510.1016/j.pmedr.2023.102555 38170022
    [Google Scholar]
11. KakuY. UriuK. KosugiY. Virological characteristics of the SARS-CoV-2 KP.2 variant.Lancet Infect. Dis.2024247e41610.1016/S1473‑3099(24)00298‑6 38782005
    [Google Scholar]
12. KakuY. UriuK. OkumuraK. ItoJ. SatoK. Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.Lancet Infect. Dis.20242410e60910.1016/S1473‑3099(24)00505‑X 39159637
    [Google Scholar]
13. KaryakarteR.P. DasR. PotdarV. Tracking KP.2 SARS-CoV-2 variant in India and the clinical profile of KP.2 cases in Maharashtra, India.Cureus2024168e6605710.7759/cureus.66057 39224723
    [Google Scholar]
14. JianF. YisimayiA. SongW. WangJ. XuY. ChenX. Humoral immunogenicity comparison of XBB and JN. 1 in human infections.bioRxiv20240419590276202410.1101/2024.04.19.590276
    [Google Scholar]
15. World Health OrganizationStatement on the antigen composition of COVID-19 vaccines.2023Available from: https://www.who.int/news-room/feature-stories/detail/how-do-vaccines-work?adgroupsurvey={adgroupsurvey}&gad_source=1&gclid=CjwKCAjwyfe4BhAWEiwAkIL8sDUp3Nsg2J2uoubKGURw-Yh2kF5xUWDgavMgG8S1R4vNtjZtNw4XeBoCpeoQAvD_BwE(accessed on 23-10-2024)
    [Google Scholar]
16. CarterL.L. YuM.A. SacksJ.A. BarnadasC. PereyaslovD. CognatS. Global genomic surveillance strategy for pathogens with pandemic and epidemic potential 2022-2032.Bull. World Health Organ.202210023910.2471/BLT.22.288220
    [Google Scholar]
17. HussainMS SharmaG The burden of cardiovascular diseases due to COVID-19 pandemic.Thorac Cardiovasc Surg2024721405010.1055/s‑0042‑175520535987194
    [Google Scholar]
18. LiP. FaraoneJ.N. HsuC.C. Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants.Cell Rep.202443811452010.1016/j.celrep.2024.114520 39024099
    [Google Scholar]
19. ZaeckL.M. TanN.H. RietdijkW.J.R. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.Nat. Commun.2024151422410.1038/s41467‑024‑48414‑x 38762522
    [Google Scholar]
20. PlaxcoA.P. KmetJ.M. NolanV.G. TaylorM.A. SmeltzerM.P. Association between mRNA vaccination and infection from SARS-CoV-2 during the delta and omicron BA.1 waves: A population-level analysis.AJPM Focus20232410015010.1016/j.focus.2023.100150 37941824
    [Google Scholar]
21. VokóZ. KissZ. SurjánG. Effectiveness and waning of protection with different SARS-CoV-2 primary and booster vaccines during the delta pandemic wave in 2021 in Hungary (HUN-VE 3 Study).Front. Immunol.20221391940810.3389/fimmu.2022.919408 35935993
    [Google Scholar]
22. KleinM.G. ChengC.J. LiiE. COVID-19 models for hospital surge capacity planning: A systematic review.Disaster Med. Public Health Prep.202216139039710.1017/dmp.2020.332 32907668
    [Google Scholar]
23. AnesiG.L. LynchY. EvansL. A conceptual and adaptable approach to hospital preparedness for acute surge events due to emerging infectious diseases.Crit. Care Explor.202024e011010.1097/CCE.0000000000000110 32426752
    [Google Scholar]
24. GilmoreB. NdejjoR. TchetchiaA. Community engagement for COVID-19 prevention and control: A rapid evidence synthesis.BMJ Glob. Health2020510e00318810.1136/bmjgh‑2020‑003188 33051285
    [Google Scholar]
25. LittlecottH. HerdC. O’RourkeJ. ChaparroL.T. KeelingM. RubinG. Effectiveness of testing, contact tracing and isolation interventions among the general population on reducing transmission of SARS-CoV-2: A systematic review. Philosoph transac Ser A.Mathem Phys Engin Sci202338120230131
    [Google Scholar]
26. GuptaG. HussainM.S. ThapaR. Hope on the horizon: Wharton’s jelly mesenchymal stem cells in the fight against COVID-19.Regen. Med.202318967567810.2217/rme‑2023‑0077 37554111
    [Google Scholar]